Search results for "Prescription"

showing 10 items of 289 documents

Local Formula with Mucoadhesive Property: A Randomized Clinical Trial of a Therapeutic Agent for the Treatment of Oral Aphthous Ulcers

2020

Background Recurrent or occasional aphthous lesions represent a painful oral condition with high prevalence. Since the etiology is still unclear and most likely related to a dysfunction in the local immune system, several treatment strategies have been proposed, including systemic agents, local agents, and laser therapy, to reduce the pain and discomfort for the patient without acting on the causes. Materials and methods The purpose of the present randomized study was to assess the clinical efficacy of a new topical gel with mucoadhesive property to reduce the pain and the dimension of the aphthosis lesions. Fifty patients presenting at least one minor ulcer were randomized to a control gro…

medicine.medical_specialtyVisual analogue scalePainPlacebolaw.invention03 medical and health sciencesOral aphthous ulcers0302 clinical medicineRandomized controlled triallawAdjuvant therapyHumansMedicineClinical significanceMedical prescriptionGeneral DentistryWound Healingbusiness.industry030206 dentistryDermatologyTreatment Outcome030220 oncology & carcinogenesisEtiologyStomatitis AphthousbusinessGelsThe Journal of Contemporary Dental Practice
researchProduct

Standardisiertes postoperatives Schmerztherapieschema in der Orthopädie

2006

In order to treat patients with postoperative acute pain effectively, we have developed a standardised algorithm for analgesia. This process includes three levels and the appropriate supply of medication. The therapy level is defined based on the scale of the operation. Accordingly, the prescription and handling of the pain medication is simplified for the attending physician and nurses. The pain level has to be measured by the nursing staff sing a visual analogue scale (VAS). Thus, the efficiency of the analgesics will be continuously evaluated and controlled. The standardised supply medication can be applied in those cases with pain levels > or = 4 (VAS). It is possible to up- or down-gra…

medicine.medical_specialtyVisual analogue scalebusiness.industryPain medicationAnalgesicGuidelinePain levelOrthopedic surgeryPhysical therapymedicineOrthopedics and Sports MedicineSurgeryMedical prescriptionbusinessPain therapyZeitschrift für Orthopädie und ihre Grenzgebiete
researchProduct

Direct Oral Anticoagulants versus Vitamin K Antagonists in Patients Aged 80 Years and Older.

2021

The effectiveness of direct oral anticoagulants (DOAC) is non-inferior to vitamin K antagonists (VKA) to treat atrial fibrillation and venous thromboembolism (VTE). In this cross-sectional study, we compared older persons taking DOACs to those taking VKAs. We included ambulatory individuals ≥80 years, affiliated to Mutualité Sociale Agricole of Burgundy, who were refunded for a medical prescription in September 2017. The demographic conditions, registered chronic diseases (RCD), and number and types of prescribed drugs were compared in the DOAC group and VKA group. Of the 3190 included individuals, 1279 (40%) were prescribed DOACs and 1911 (60%) VKAs. Individuals taking VKAs were older than…

medicine.medical_specialtyVitamin KDigoxinmedicine.drug_classHealth Toxicology and MutagenesisAdministration Oral030204 cardiovascular system & hematologyVitamin kdirect oral anticoagulantsArticle03 medical and health sciences0302 clinical medicineInternal medicineAtrial FibrillationMedicineHumans030212 general & internal medicineMedical prescriptionAgedAged 80 and overbusiness.industryAnticoagulantanticoagulantPublic Health Environmental and Occupational HealthRFurosemideAnticoagulantsAtrial fibrillationVenous Thromboembolismmedicine.diseaseaged 80 and overvitamin K antagonistsCross-Sectional StudiesHeart failureAmbulatoryMedicineFemalebusinessmedicine.drugInternational journal of environmental research and public health
researchProduct

Kidney Disease Management in the Hospital Setting: A Focus on Inappropriate Drug Prescriptions in Older Patients

2021

Aging with multimorbidity and polytherapy are the most significant factors that could led to inappropriate prescribing of contraindicated medications in patients with chronic kidney disease (CKD). The aim of this study was to evaluate the prescriptions of contraindicated drugs in older adults in CKD and to identify their associated factors in a hospital context. An observational retrospective study was carried out considering all patients ≥65 years with at least one serum creatinine value recorded into the REPOSI register into 2010–2016 period. The estimated glomerular filtration rate (eGFR) was applied to identify CKD. A descriptive analysis was performed to compare demographic and clinica…

medicine.medical_specialtyappropriateness of prescriptionprescribing patternsRenal functionContext (language use)RM1-950Logistic regressionNOchemistry.chemical_compoundolder patientInternal medicinehospital settingmedicinePharmacology (medical)LS4_4Medical prescriptionprescribing patternappropriateness of prescriptions chronic kidney disease hospital setting older patients prescribing patterns real-world data.Original ResearchPharmacologyCreatininereal-world databusiness.industryRetrospective cohort studymedicine.diseaseolder patientsreal-world data.appropriateness of prescriptions; chronic kidney disease; hospital setting; older patients; prescribing patterns; real-world dataappropriateness of prescriptionschemistryObservational studyTherapeutics. Pharmacologybusinesschronic kidney diseaseKidney diseaseFrontiers in Pharmacology
researchProduct

Muscular failure training in conditioninig neuromuscular programs

2010

Many recommendations for designing of resistance training programs are suggested training all the sets to perform until voluntary fatigue with a maximum load selected, situation known as muscular failure. However, recent evidence has emerged that suggest caution in the prescription of training to failure in both, healthy and performance perspective. This review has addressed to this issue and made a collection of literature and a qualitative analysis of this topic. Final conclusion of this study suggest that implementation of the muscular failure resistance training is not recommended in subjects who trained with healthy goals, because it breaks the acceptable risk-benefit ratio in healthy …

medicine.medical_specialtybiologybusiness.industryAthleteseducationResistance trainingPhysical Therapy Sports Therapy and Rehabilitationmuscular fatigueTraining to failurebiology.organism_classificationTraining (civil)Muscular fatigueResistance trainingrecoveryQualitative analysisRecoveryMuscular fatiguePhysical therapyEducación Física y DeportivaMedicineMedical prescriptionresistance traininglcsh:Sports medicinebusinesslcsh:RC1200-1245
researchProduct

Legal liability in bisphosphonate-related osteonecrosis of the jaw

2014

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) is an adverse reaction that may occur in patients administered with bisphosphonates (BP). This condition can cause high morbidity and hinder quality of life. Its treatment is complex and often unsatisfactory, and prevention strategies may have limited effectiveness, if any. Thus, managing patients treated with BP may result in exposure of the practitioner to legal liability or malpractice claims: legal actions pursuant to BRONJ are reported to be underway on three continents. Nonetheless, the attribution of liability, if any, is a complex process requiring, on the basis of current knowledge, a robust and pragmatic approach to the facts…

medicine.medical_specialtybisphosphonate jawLegal liabilitybusiness.industrymedicine.medical_treatmentLiabilitySettore MED/50 - Scienze Tecniche Mediche ApplicateLiability LegalBisphosphonatemedicine.diseaseSurgeryQuality of life (healthcare)Settore MED/28 - Malattie OdontostomatologicheMalpracticemedicineHumansBisphosphonate-Associated Osteonecrosis of the JawCausationMedical prescriptionOsteonecrosis of the jawIntensive care medicinebusinessGeneral Dentistry
researchProduct

Indications of PCSK9 inhibitors in clinical practice. Recommendations of the Spanish Society of Arteriosclerosis (SEA), 2019

2019

A group of experts convened by the Spanish Society of Arteriosclerosis (SEA) has been in charge of updating the SEA document on the indications of PCSK9 inhibitors (PCSK9i) in clinical practice that was published in 2016. This update is justified by the fact that the data from clinical trials carried out on a large scale with PCSK9i have shown that in addition to their high potency to lower atherogenic cholesterol, they reduce the risk of atherosclerotic cardiovascular disease, both in patients with stable disease, and with recent disease, and with a high degree of security. This update provides the recommendations and level of evidence for the prescription of iPCSK9 in patients with homozy…

medicine.medical_specialtybusiness.industryGeneral EngineeringFamilial hypercholesterolemiaArteriosclerosisDiseaseEvidence-based medicinemedicine.diseaseClinical trialStable DiseasemedicineGeneral Earth and Planetary SciencesMedical prescriptionPCSK9 InhibitorsIntensive care medicinebusinessGeneral Environmental ScienceClínica e Investigación en Arteriosclerosis (English Edition)
researchProduct

FRI0318 Health care resource utilisation (HCRU) and cost analyses of systemic lupus erythematosus (SLE) as a function of disease severity: analysis o…

2018

Background SLE is a severe, chronic autoimmune disease of the connective tissue involving multiple organ systems. Understanding the economic burden of SLE in the context of disease severity is important when considering new therapeutic options. Objectives HCRU and costs associated with SLE were examined retrospectively using anonymized data from a German Sickness Fund database. Methods Real-world claims for adult (≥18 years old) patients (pts) with SLE from a German Sickness Fund database of company health insurance schemes were analysed. HCRU and costs were assessed annually for 2009–2014 for pts diagnosed with SLE in 2009 and validated using repeated SLE-related claims, co-diagnosis codes…

medicine.medical_specialtybusiness.industryIncidence (epidemiology)SpecialtyContext (language use)macromolecular substancesDisease severityInternal medicineClaims dataHealth caremedicineMedical prescriptionskin and connective tissue diseasesbusinessOrgan systemFRIDAY, 15 JUNE 2018
researchProduct

PS8:160 Health care resource use (hru) and medical cost analyses as a function of systemic lupus erythematosus (sle) disease severity: analysis of cl…

2018

Purpose Real-world HRU and medical cost analyses support drug development in SLE. The economic burden of SLE as a function of disease severity was quantified for a German cohort. Methods HRU and cost analyses were performed for patients (≥18 years old) with SLE and compared with those of matched controls for 2009–2014 using the Betriebskrankenkassen (BKK) German Sickness Fund Database. BKK is a branch of the statutory German health insurance. SLE was confirmed in 2009 using the diagnosing physician’s specialty, repeated SLE-related claims, co-diagnosis codes, laboratory tests, or prescriptions. At least 3 years’ data was also required prior to 2009. SLE cases were control matched by age, se…

medicine.medical_specialtybusiness.industryIncidence (epidemiology)SpecialtyDisease severityimmune system diseasesInternal medicineClaims dataCohortHealth caremedicineResource useMedical prescriptionskin and connective tissue diseasesbusinessPoster session 8: Registries and cohorts
researchProduct

Documentation of Severe Pain, Opioid Doses, and Opioid-Related Side Effects in Outpatients with Cancer

1999

Pain severity, prescribed opioids including "rescue" medication for breakthrough pain, bowel movements, and laxative prescription were evaluated in 54 cancer patients treated in an outpatient department devoted to hematology and oncology during 1996. Median number of visits per patient was 5.5 (range 1-48), and median duration of patient care during opioid therapy was 44.5 days (range 1-363). Pain severity and opioid dose were not documented, or documented in less than 25% of visits, in 62.9% and 48.2%, respectively. Rescue doses for breakthrough pain, laxative prescription and bowel movements were never mentioned in 70.4%, 68.5%, and 87% respectively, of all patient charts. Only 3 of 12 ph…

medicine.medical_specialtybusiness.industryVisual analogue scaleRetrospective cohort studyAnesthesiology and Pain MedicineOpioidPain assessmentInternal medicineAnesthesiaAmbulatoryMedicineOutpatient clinicNeurology (clinical)Medical prescriptionbusinessCancer painGeneral Nursingmedicine.drugJournal of Pain and Symptom Management
researchProduct